Pyrotinib clinical trials
Pyrotinib is named as an intervention in 51 current clinical trials in our China register. 33 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (6). The most-studied condition is Breast Cancer.
How Pyrotinib works
All drug targets →- Epidermal growth factor receptor erbB1 inhibitor InhibitorTarget: EGFR epidermal growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Receptor protein-tyrosine kinase erbB-2 inhibitor InhibitorTarget: ERBB2 erb-b2 receptor tyrosine kinase 2✓ In ChEMBL and the Guide to Pharmacology
- Breast cancerPhase 3
- Non-small cell lung carcinomaPhase 3
- Biliary tract cancerPhase 2
- CancerPhase 2
- Colorectal cancerPhase 2
- Esophageal adenocarcinomaPhase 2
- Esophageal squamous cell carcinomaPhase 2
- Gastric cancerPhase 2
- Hepatocellular carcinomaPhase 2
- Lung adenocarcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3647420, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9662, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Pyrotinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Pyrotinib
- ChEMBL
- CHEMBL3647420
- DrugBank
- DB14993
- PubChem CID
- 51039030
- CAS number
- 1269662-73-8
- FDA UNII
- CJN36EQM0H
- Wikidata
- Q27275495
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Pyrotinib
51 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Pyrotinib
43 conditionsAll 43 conditions
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 16 |
| HER2-positive Breast Cancer | 7 |
| Advanced Breast Cancer | 4 |
| HER2 + Breast Cancer | 4 |
| Metastatic Breast Cancer | 2 |
| Hormone Receptor-Positive Breast Cancer | 2 |
| Non-small Cell Lung Cancer | 2 |
| Breast Cancer Invasive | 2 |
| Breast Neoplasm Female | 1 |
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Lung Cancer Stage III | 1 |
| Mutation | 1 |
| HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | 1 |
| Breast Cancer Metastatic | 1 |
| Breast Cancer Brain Metastases | 1 |
| Breast Neoplasm | 1 |
| Breast Tumors | 1 |
| Triple-Negative Breast Cancer (TNBC) | 1 |
| Advanced/ Metastatic Her-2 Positive Breast Cancer | 1 |
| HER2-positive Early Breast Cancer | 1 |
| HER2 Positive Breast Cancer | 1 |
| Pyrotinib Treatment | 1 |
| HER2-low-expressing Breast Cancer | 1 |
| Hormone Receptor-positive Breast Cancer | 1 |
| Neoadjuvant Therapy | 1 |
| Breast Cancer Stage I | 1 |
| Hormone-receptor Positive Breast Cancer | 1 |
| Advanced/Metastatic Breast Cancer | 1 |
| HER2-Positive Metastatic Breast Cancer | 1 |
| Breast Cancer Female | 1 |
| Metastatic Breast Cancer (MBC) | 1 |
| HER2-Positive Breast Cancer | 1 |
| HER2-positive Metastatic Breast Cancer | 1 |
| First-line Treatment | 1 |
| Breast Neoplasms | 1 |
| Locally Advanced Breast Cancer | 1 |
| Advanced Digestive System Tumor | 1 |
| Early-stage Breast Cancer | 1 |
| HER2-expressing Advanced Solid Tumors | 1 |
| Adjuvant Therapy | 1 |
| Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 1 |
Sponsors
lead sponsor per trial+ 12 more sponsors in the trial list above.
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 51 | 33 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Pyrotinib trials
How many clinical trials are testing Pyrotinib?
51 current trials in our China register name Pyrotinib (also registered as SHR1258) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Pyrotinib trials recruiting patients?
Yes. 33 of the 51 trials are recruiting: 33 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Pyrotinib clinical trials?
Fudan University (6), Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5), Shanghai Jiao Tong University School of Medicine (4) and Shengjing Hospital (3), among 27 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pyrotinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pyrotinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pyrotinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.